ARTICLE
Belsomra vs Dayvigo vs Quviviq — the three orexin antagonists compared
Three drugs, one mechanism, and a single axis that separates them. Once you can see where each one sits on it, the choice stops being a brand question.
There are exactly three dual orexin receptor antagonists approved in the United States. Belsomra (suvorexant) came first, in August 2014, and established the class. Dayvigo (lemborexant) followed in December 2019. Quviviq (daridorexant) arrived in January 2022. All three work by blocking orexin — the signal your brain uses to hold you awake — rather than by sedating you, which is what separates this class from the Z-drugs and benzodiazepines that came before it.
Because they share a mechanism, the interesting differences are narrow, and nearly all of them trace back to a single number: how long the drug stays active. Quviviq clears fastest, Belsomra sits in the middle, Dayvigo lasts longest. Where a drug falls on that line determines both how much of your night it covers and how much of it is still with you at breakfast. This page is the map of the whole class; the head-to-head comparisons linked near the end are the detail.
| Quviviqdaridorexant | Belsomrasuvorexant | Dayvigolemborexant | |
|---|---|---|---|
| Mechanism | Dual orexin receptor antagonist — blocks both OX1 and OX2 to remove the wake signal; does not sedate | Dual orexin receptor antagonist — the same OX1 and OX2 mechanism, and the first drug of the class | Dual orexin receptor antagonist — blocks both OX1 and OX2, not one selectively; dissociates from the receptor faster than suvorexant |
| FDA approval | January 2022 — the newest of the three | August 13, 2014 — the first DORA ever approved | December 2019 |
| Half-life | ~8 hours — the shortest in the class, engineered short to limit next-day effects | ~12 hours (mean t½, 95% CI 12–13) — the middle of the class | The longest of the three: effective ~17–39 h, terminal ~45–55 h (commonly quoted as 17 h at 5 mg and 19 h at 10 mg — a single figure misrepresents it) |
| Standard dose | 25 mg or 50 mg once nightly, within 30 minutes of bed, with at least 7 hours before you plan to wake | 10 mg once nightly within 30 minutes of bed, with at least 7 hours before you plan to wake; may be increased but not to exceed 20 mg | 5 mg once nightly at bedtime, may be increased to a 10 mg maximum, with at least 7 hours before you plan to wake |
| Next-morning residual risk | Lowest of the three — the shortest half-life means the least drug remaining by morning | Middle — the label states driving ability was impaired in some individuals taking 20 mg. The FDA advisory committee rejected the proposed 40 mg dose in May 2013 over next-day residual sleepiness and impaired driving | Highest — measurable driving-simulator impairment 8–9 hours after the 10 mg dose, and the label warns against next-morning driving at 10 mg |
| AASM guideline position | Not named — approved five years after the 2017 guideline, so it was never assessed in it | The only orexin antagonist the guideline addresses: a weak recommendation for sleep-maintenance insomnia | Not named — approved after the 2017 guideline was published |
| Cost & generic availability | No generic — roughly $500 a month | No generic. Broadly similar to Dayvigo and cheaper than Quviviq, but still expensive. One generic application holds tentative FDA approval only, which does not permit marketing, and the composition-of-matter patent runs to 2029 | No generic — roughly $350 a month |
| Dependence & rebound | Low — little signal of tolerance, dependence, or withdrawal across the orexin antagonist class | In completed clinical trials there was no evidence of physical dependence with prolonged use, and no reported withdrawal symptoms after discontinuation | Low — the same class profile; little signal of tolerance, dependence, or withdrawal across the orexin antagonists |
| Controlled-substance status | Schedule IV | Schedule IV | Schedule IV |
| Manufacturer | Idorsia | Merck | Eisai |
One mechanism, three half-lives — the axis that separates them
Start with what is not different, because it is most of the picture. Belsomra, Dayvigo, and Quviviq are all dual orexin receptor antagonists. Each blocks orexin at both of its receptors, OX1 and OX2, and none of them is selective for one over the other — worth stating because Dayvigo is sometimes described as OX2-selective and it is not. None of the three sedates you the way a Z-drug or a benzodiazepine does; they remove a wake signal rather than adding a sleep signal. All three are Schedule IV, all three are prescription-only, and all three carry the same class cautions: next-day drowsiness, and rare complex sleep behaviors.
What separates them is how long each one stays active, and the three line up cleanly along it. Quviviq's half-life is about 8 hours — the shortest in the class, and a deliberate design choice; daridorexant was engineered to clear quickly, specifically to limit next-day residue. Belsomra sits in the middle, with a mean terminal half-life of approximately 12 hours (95% CI 12 to 13). Dayvigo is the longest and the hardest to state in a single number: commonly quoted as 17 hours at 5 mg and 19 hours at 10 mg, its underlying pharmacokinetics show an effective half-life somewhere between about 17 and 39 hours and a terminal half-life closer to 45 to 55 hours. However you frame that last one, the ordering does not change.
Everything practical follows from that ordering. A shorter half-life means less drug on board when the alarm goes off — less fog, less residual impairment — but potentially less coverage in the second half of the night. A longer half-life means the reverse: more of the night covered, at the cost of more drug still present in the morning. Neither end of the axis is better in the abstract. The two things that do not follow from half-life are the two asymmetries worth holding separately: Belsomra is the only one of the three with a guideline recommendation behind it, and Dayvigo carries the strongest next-morning driving caution.
Where each one sits on the axis
Same mechanism, three positions. Here is what each one buys you, and what it costs.
Quviviq — the shortest half-life, the cleanest mornings
Quviviq's roughly 8-hour half-life is its entire case. If you wake up feeling drugged on other sleep medications, if you drive or do anything cognitively demanding first thing, or if next-day fog is the side effect you most want to avoid, the fastest clearance in the class is working in your favor. It is dosed at 25 mg or 50 mg once nightly, taken within 30 minutes of bed with at least 7 hours available before you plan to wake.
The trade-offs are three. It reaches least far into the night, so if your problem is a 4am awakening, a fast-clearing drug may already be fading by the time you need it. It is the most expensive of the three at roughly $500 a month, with no generic. And it is absent from the AASM guideline — not because it was assessed and passed over, but because it was approved in 2022, five years after that guideline was published. Absence there is a date, not a verdict.
Belsomra — the middle of the axis, and the only guideline recognition
Belsomra is the original DORA and the only one the American Academy of Sleep Medicine's pharmacologic guideline addresses: a weak recommendation for sleep-maintenance insomnia — the trouble-staying-asleep pattern, as opposed to trouble falling asleep. That recommendation is weak in the guideline's own grading, but it is more than the other two have, and it comes alongside about a decade of real-world prescribing. The recommended dose is 10 mg once nightly within 30 minutes of bed, with at least 7 hours before you plan to wake, increasable but not above 20 mg.
That 20 mg ceiling is the other half of Belsomra's story, and it has a documented history. When Merck sought approval, it proposed higher doses than the ones that reached the market; in May 2013 the FDA's advisory committee reviewed the data and rejected the 40 mg dose, citing next-day residual sleepiness and impaired driving performance. The label states that driving ability was impaired in some individuals taking 20 mg, and patients on that dose are cautioned against next-day driving. A 12-hour half-life is the middle of this class, not a short one.
Dayvigo — the longest reach, and the strongest driving caution
Dayvigo's duration is its argument. If the dominant problem is waking in the small hours and not getting back down, a drug still meaningfully present at 4am covers exactly that gap — which is why the longest half-life in the class is a feature and not only a liability. It is dosed at 5 mg once nightly at bedtime, increasable to a 10 mg maximum, again with at least 7 hours before you plan to wake.
The liability is real, and concentrated at the higher dose. Driving-simulator studies found measurable next-morning impairment 8 to 9 hours after the 10 mg dose, and Dayvigo's label carries an explicit warning against next-morning driving at that dose. Dayvigo makes the most sense when early-hours waking is the dominant complaint and your mornings can absorb some residual drug — a judgment to make with a prescriber, not alone.
How to choose — which half of your night is broken
The useful question is not which of the three is best. It is which half of your night is failing. Sleep-onset insomnia — lying awake at the start of the night, unable to drop off — asks less of a drug's duration, because the job is finished in the first hour or two. Sleep-maintenance insomnia — falling asleep normally and then surfacing at 2, 3, or 4am — asks the opposite, because the drug has to still be doing something hours after you took it. Most people can tell which one describes them after a week of honest logging, and plenty discover they have both.
Map that onto the axis and the shortlist writes itself. If onset is the problem and your mornings are non-negotiable — you drive, you operate machinery, you have young children, your work is cognitively demanding at 8am — the short end of the axis is where to look. If maintenance is the problem and your mornings have some slack in them, the long end has more to offer. Belsomra's position in the middle is a genuine middle: some late coverage, some morning residue, plus the only guideline recommendation of the three.
One practical rule applies to all three, and it is about your wake time rather than your bedtime. Every one of them is dosed with at least 7 hours available before you plan to be up. If your alarm goes at 6am, the pill has to be taken by 11pm — not as a preference, but as a labeled condition of taking it safely. Anchor the decision to when you have to be awake and functioning, not to when you feel like going to bed.
The honest part — an advance on dependence, not a cure
The orexin antagonists are a real improvement on what came before, and it is worth being specific about what the improvement is. Across the class there is little signal of tolerance, dependence, or withdrawal — in Belsomra's completed clinical trials there was no evidence of physical dependence with prolonged use and no reported withdrawal symptoms after discontinuation. Set against the Z-drugs and benzodiazepines, where tolerance and rebound insomnia are expected features of longer use, that is a meaningful change. None of the three carries a boxed warning.
What none of them does is treat the thing generating the insomnia. They suppress a wake signal for one night at a time. The nervous system producing 3am arousals is unchanged in the morning, which is why the same guideline that names one of these drugs puts cognitive behavioral therapy for insomnia first for chronic insomnia — and why stopping any of the three tends to return you to where you started. If your nights look like tired but wired — exhausted all day, alert the moment your head hits the pillow — that pattern is the actual target, and the 6-week program is the structured route at it. The full alternatives map covers what exists outside this class, including the options that are not drugs at all.
The head-to-head comparisons
This page is the map of the class. Each of these takes one pairing and works it out in detail.
Quviviq vs Belsomra — decides between the shortest half-life and the only guideline recommendation. The one to read if evidence base and morning clarity are pulling you in opposite directions.
Quviviq vs Dayvigo — decides between the two ends of the axis, shortest against longest. The one to read if you are weighing morning residue against late-night coverage.
Quviviq vs Ambien — steps outside the class entirely, if what you are really weighing is an orexin antagonist against an older sedative with a generic, a boxed warning, and a dependence profile.
The full Quviviq alternatives guide — the wider map, including the out-of-class prescription options and why CBT-I remains first-line.
The strongest OTC sleep aids, ranked honestly — the pillar guide to the non-prescription landscape, if a milder approach is what you are weighing.
Tired but wired — the hyperarousal pattern that none of these three resolves on its own.
The 6-week program — CBT-I as a structured path, the treatment recommended first-line for chronic insomnia.
Frequently asked questions
Which orexin antagonist is best?
None of them is best in the abstract, because they share a mechanism and differ mainly in how long they stay active. The honest framing is which one fits the half of your night that is failing. Quviviq's roughly 8-hour half-life is the shortest, so it leaves the least next-morning residue and suits people whose mornings have to be sharp. Dayvigo's effective half-life is the longest, so it reaches furthest into the night and suits early-hours waking — at the cost of a label warning against next-morning driving at the 10 mg dose. Belsomra sits between them at around 12 hours and is the only one the AASM guideline addresses, with a weak recommendation for sleep-maintenance insomnia. These have not been tested head-to-head against each other, so nobody can hand you a ranking backed by direct evidence. The choice belongs to a prescriber who knows your pattern and your medication list.
What is the difference between Belsomra, Dayvigo, and Quviviq?
Mechanically, very little: all three are dual orexin receptor antagonists that block both OX1 and OX2 to remove the brain's wake signal rather than sedating you, and all three are Schedule IV and prescription-only. The practical differences are half-life, guideline status, and price. Quviviq (approved January 2022) has a half-life of about 8 hours; Belsomra (August 2014, the first of the class) has a mean terminal half-life of approximately 12 hours; Dayvigo (December 2019) has the longest effective half-life of the three. Belsomra is the only one named in the AASM's 2017 pharmacologic guideline, which is partly a matter of timing — Dayvigo and Quviviq were both approved after it was published. Quviviq runs roughly $500 a month, Dayvigo around $350, and Belsomra broadly similar to Dayvigo. None has a generic.
Which orexin antagonist has the fewest side effects?
The class shares a side-effect profile — next-day drowsiness and rare complex sleep behaviors are cautions on all three — so the meaningful question is which one leaves the least drug in you by morning, and that tracks half-life. Quviviq clears fastest at about 8 hours, which is why it carries the lowest next-morning residual burden of the three. Dayvigo sits at the other end: driving-simulator studies found measurable impairment 8 to 9 hours after the 10 mg dose, and its label warns against next-morning driving at that dose. Belsomra is in between, and its own history illustrates the point — the FDA advisory committee rejected the proposed 40 mg dose in May 2013 over next-day residual sleepiness and impaired driving, and the label notes that driving was impaired in some individuals at 20 mg. That said, individual response varies enough that the drug with the best profile on paper is not automatically the one that suits you.
Can you switch between them?
Switching within the class is a normal clinical conversation — people move between these drugs when one is not working, is not covered, or leaves too much morning residue. What it is not is a swap you make yourself. The three are not interchangeable milligram for milligram; their doses and half-lives are different, and moving from a longer-acting drug to a shorter one (or the reverse) changes both how much of your night is covered and how much drug is present when you wake. Because all three are cleared primarily through CYP3A, the rest of your medication list matters to the decision too. Take the reason for switching to your prescriber — poor coverage, morning grogginess, cost, or coverage denial are all legitimate ones — and let them handle the timing and the dose.
Is there a generic for any of them?
No. As of now, none of the three orexin antagonists is available as a generic in the United States, which is the main reason all three are expensive and why insurance coverage is usually the deciding factor in practice. Belsomra is the closest, being the oldest: one generic application holds tentative FDA approval, but tentative approval does not permit marketing, and the composition-of-matter patent runs to 2029. Quviviq and Dayvigo are both newer and further from generic entry. If cost is the binding constraint, that is worth saying plainly to a prescriber — the alternatives worth discussing may be outside this class entirely, including generic options with different trade-offs and non-drug treatment, which the full alternatives guide covers.
Sources
- U.S. Food and Drug Administration (FDA) — Prescribing Information for QUVIVIQ (daridorexant), Idorsia Pharmaceuticals: dual orexin receptor antagonism, Schedule IV status, ~8-hour half-life, 25 mg / 50 mg dosing within 30 minutes of bed with at least 7 hours before awakening, CYP3A metabolism, and class warnings (next-day somnolence, complex sleep behaviors).
- U.S. Food and Drug Administration (FDA) — Prescribing Information for BELSOMRA (suvorexant), Merck Sharp & Dohme: dual orexin receptor antagonism at OX1R and OX2R, Schedule IV status, mean terminal half-life of approximately 12 hours (95% CI 12–13), the 10 mg recommended dose and 20 mg maximum taken within 30 minutes of bed with at least 7 hours before awakening, CYP3A as the major elimination pathway, the finding that driving ability was impaired in some individuals taking 20 mg, and Section 9.3 reporting no evidence of physical dependence with prolonged use and no withdrawal symptoms after discontinuation.
- U.S. Food and Drug Administration (FDA) — Prescribing Information for DAYVIGO (lemborexant), Eisai Inc.: dual orexin receptor antagonism, Schedule IV status, half-life and pharmacokinetics, 5 mg / 10 mg dosing, CYP3A metabolism, and the warning against next-morning driving at the 10 mg dose.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349. Source for the weak recommendation for suvorexant in sleep-maintenance insomnia, and for CBT-I as first-line treatment for chronic insomnia.
- De Crescenzo F, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–184.
- Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125–139.